Claims
- 1. A method of delivering a drug to a mucosal surface of a mammal or to the vicinity of a mucosal surface of a mammal to provide a therapeutic effect on or in the vicinity of the mucosal surface, which method comprises the steps of:
- a) adhering to the mucosal surface a transmucosal drug delivery device in the form of a sheet material having a surface comprising:
- 1) a particulate polymeric resin comprising carboxylic acid containing monomer units and having an average particle size of less than or equal to about 100 mm;
- 2) from about 10 parts to about 200 parts by weight of a polytetrafluoroethylene support matrix based on 100 parts by weight of the resin; and
- 3) an amount of a drug effective to provide a desired therapeutic result;
- which composition contains less than about 10% water by weight based on the weight of the polymeric resin, and adheres to a mucosal surface to release the drug to the mucosal surface;
- b) allowing the device to remain adhered so as to release the drug to the mucosal surface or to the vicinity of the mucosal surface.
- 2. The method according to claim 1 wherein the transmucosal drug delivery device further comprises a flexible film backing on one side of the device.
- 3. The method according to claim 2, wherein the flexible film backing is impermeable to the drug.
- 4. The method according to claim 2, wherein the flexible film backing occludes all of the surface area of the patch other than that surface that is intended to be adhered to the mucosal surface.
- 5. The method according to claim 2, wherein the flexible film backing is insoluble in fluids endogenous to the mucosal surface.
- 6. The method according to claim 2, wherein the flexible film backing is selected from the group consisting of celluloses, polyvinyl alcohols, shellac, zein, a silicone elastomer, a polymethacrylate, and a copolymer of acrylic and a methacrylic acid ester containing quaternary ammonium groups.
- 7. The method according to claim 6, wherein the flexible film backing is zein or ethylcellulose.
- 8. The method according to claim 1, wherein the resin contains at least about 55% by weight of carboxylic acid moieties based on the total weight of the resin.
- 9. The method according to claim 1, wherein the monomer is acrylic acid, maleic acid, itaconic acid, citraconic acid, or methacrylic acid, or a combination thereof.
- 10. The method according to claim 1, wherein the monomer is acrylic acid.
- 11. The method according to claim 1, wherein the resin has an average particle size of between about 1 mm and about 80 mm.
- 12. The method according to claim 1, wherein the resin has an average particle size of between about 1 mm and about 30 mm.
- 13. The method according to claim 1, wherein the resin has an average particle size of between about 2 mm and about 10 mm.
- 14. The method according to claim 1, wherein the resin has a water content of less than about 6% based on the total weight of the resin.
- 15. The method according to claim 1, wherein the device comprises about 10 parts to about 100 parts by weight of a polytetrafluoroethylene support matrix, based on 100 parts by weight of the resin.
- 16. The method according to claim 1, wherein said drug is delivered systemically across a mucosal surface.
Parent Case Info
This is a continuation of application Ser. No. 07,885,282 filed May 18, 1992, abandoned.
US Referenced Citations (25)
Foreign Referenced Citations (3)
Number |
Date |
Country |
304536 |
Mar 1989 |
EPX |
56-068608 |
Jun 1981 |
JPX |
9002511 |
Mar 1990 |
WOX |
Non-Patent Literature Citations (1)
Entry |
Chem. Abstracts 99:93643u. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
885282 |
May 1992 |
|